Cantor Fitzgerald Reiterates Overweight on Longboard Pharmaceuticals, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Longboard Pharmaceuticals (NASDAQ:LBPH) and maintained a $90 price target.
August 02, 2024 | 3:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Longboard Pharmaceuticals (NASDAQ:LBPH) and maintained a $90 price target.
The reiteration of an Overweight rating and a high price target of $90 by a reputable analyst from Cantor Fitzgerald is likely to positively impact the stock price of Longboard Pharmaceuticals in the short term. This indicates strong confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100